

Biocon Biologics expands footprint in emerging markets

05 July 2023 | News

Takes over the commercialisation of biosimilars business from Viatris in 70+ countries



Bengaluru-based Biocon Biologics has completed the integration of the acquired biosimilars business in over 70 countries in Emerging Markets effective July 1, 2023, increasing the scale and scope of its business.

Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries.

The existing commercialised portfolio of biosimilars, including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, managed by Viatris in these markets, is now a part of Biocon Biologics' commercial organisation.

The company will work with existing and new partners to expand its footprint and strengthen business presence in these countries. Its best-in-class R&D capabilities, high-quality manufacturing, supply chain excellence, and commercial and regulatory expertise will enable the company to expand access to a diverse portfolio of biosimilars, meet patients' needs and be a trusted partner to patients and the healthcare community in these markets.

All the biosimilar products commercialised by Viatris in various markets such as bGlargine (Semglee), bPegfilgrastim (Fulphila), bTrastuzumab (Ogivri), bBevacizumab (Abevmy) and in-licensed product bAdalimumab (Hulio), will continue to serve patients' needs. Most of these have been co-developed with Biocon Biologics and manufactured at its world class facilities in India and Malaysia. The diverse portfolio covers key therapeutic areas of cancer, diabetes and autoimmune disease.